Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells

Experimental Cell Research

Volumn 317, Issue 15, 2011, Pages 2073-2085

  Alves, Tercia Rodrigues ^a,b   da Fonseca, Anna Carolina Carvalho ^b   Nunes, Sara Santana ^a,e   da Silva, Aline Oliveira ^a   Dubois, Luiz Gustavo Feijó ^b   Faria, Jane ^b   Kahn, Suzana Assad ^b   Viana, Nathan Bessa ^b   Marcondes, Jorge ^b   Legrand, Chantal ^c,d   Moura Neto, Vivaldo ^b   Morandi, Verônica ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d INSERM   (France)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Angiogenesis; Anoikis; Glioma; Tenascin C; Tubulogenesis

Indexed keywords

FIBRONECTIN; TENASCIN;

ANIMAL CELL; ANOIKIS; ARTICLE; CELL ADHESION; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

EID: 79960842940     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.06.006     Document Type: Article

References (69)

1. Re F., Zanetti A., Polentarutti N., Lanfrancone L., Dejana E., Colotta F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J. Cell Biol. 1994, 127:537-546.
2. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
3. Frisch S.M., Vuori K., Ruoslahti E., Chan-Hui P.Y. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 1996, 134:793-799.
4. Delaney C.E., Weagant B.T., Addison C.L. The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Exp. Cell Res. 2006, 312:2476.
5. Park C.C., Zhang H.J., Yao E.S., Park C.J., Bissell M.J. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008, 68:4398-4405.
6. Gaengel K., Genové G., Armulik A., Betsholtz C. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:630-638.
7. Dvorak H.F. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am. J. Pathol. 2003, 162:1747-1757.
8. De Bock K., Cauwenberghs S., Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr. Opin. Genet. Dev. Nov 2010, 22. [Epub ahead of print].
9. Murphy-Ullrich J. The de-adhesive activity of matricellular proteins-is intermediate cell adhesion an adaptative state?. J. Clin. Invest. 2001, 107:785-790.
10. Midwood K.S., Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal. 2009, 3:287-310.
11. Bellail A.C., Hunter S.B., Brat D.J., Tan C., Van Meir E.G. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 2004, 36:1046-1069.
12. Wang D., Anderson J.C., Gladson C.L. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol. 2005, 15:318-326.
13. Behrem S., Zarkovic K., Eskinja N., Jonic N. Distribution pattern of tenascin-C in glioblastoma-correlation with angiogenesis and tumor cell proliferation. Pathol. Oncol. Res. 2005, 11:229-235.
14. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244:143-163.
15. Zagzag D., Shiff B., Jallo G.I., Greco M.A., Blanco C., Cohen H., Hukin J., Allen J.C., Friedlander D.R. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 2002, 62:2660-2668.
16. Chung C.Y., Murphy-Ullrich J.E., Erickson H.P. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell 1996, 7:883-892.
17. Saito Y., Shiota Y., Nihisaka M., Owaki T., Shimamura M., Fukai F. Inhibition of angiogenesis by a tenascin-C peptide which is capable of activating beta1-integrins. Biol. Pharm. Bull. 2008, 31:1003-1007.
18. Inaguma Y., Kusakabe M., Mackie E.J., Pearson C.A., Chiquet-Ehrismann R., Sakakura T. Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis. Dev. Biol. 1988, 128:245-255.
19. Howeedy A.A., Virtanen I., Laitinen L., Gould N.S., Koukoulis G.K., Gould V.E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest. 1990, 63:798-806.
20. Ramos D.M., Chen B., Regezi J., Zardi L., Pytela R. Tenascin-C matrix assembly in oral squamous cell carcinoma. Int. J. Cancer 1998, 75:680-687.
21. Jahkola T., Toivonen T., Virtanen I., von Smitten K., Nordling S., von Boguslawski K., Haglund C., Nevanlinna H., Blomqvist C. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br. J. Cancer 1998, 78:1507-1513.
22. Suwiwat S., Ricciardelli C., Tammi R., Tammi M., Auvinen P., Kosma V.M., LeBaron R.G., Raymond W.A., Tilley W.D., Horsfall D.J. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 2004, 10:2491-2498.
23. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983, 43:2796-2805.
24. Bourdon M.A., Matthews T.J., Pizzo S.V., Bigner D.D. Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J. Cell. Biochem. 1985, 28:183-195.
25. Herold-Mende C., Mueller M.M., Bonsanto M.M., Schmitt H.P., Kunze S., Steiner H.H. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer 2002, 98:362-369.
26. Leins A., Riva P., Lindstedt R., Davidoff M.S., Mehraein P., Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003, 98:2430-2439.
27. Hirata E., Arakawa Y., Shirahata M., Yamaguchi M., Kishi Y., Okada T., Takahashi J.A., Matsuda M., Hashimoto N. Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 2009, 100:1451-1459.
28. Mathura K.R., Bouma G., Ince C. Abnormal microcirculation in brain tumors during surgery. Lancet 2001, 358:1698-1699.
29. Munn L.L. Aberrant vascular architecture in tumor and its importance in drug-based therapies. Drugs Discov. Today 2003, 8:396-403.
30. Jain R.K. Antiangiogenic therapy for cancer. Current and emerging concepts. Oncology 2005, 19:7-16.
31. Ghosh K., Thodeti C.K., Dudley A.C., Mammoto A., Klagsbrun M., Ingber D.E. Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc. Natl. Acad. Sci. U S A 2008, 105:11305-11310.
32. Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. Cancer Treat. Res. 2004, 17:249-262.
33. Bart J., Groen H.J.M., Hendrikse N.H., de Graaf W.T.A., Vaalburg W., de Vries E.G. The blood-brain barrier and oncology - new insights into function and modulation. Cancer Treat. Rev. 2000, 26:449-462.
34. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Ivest. 1973, 52:2745-2756.
35. Trentin A.G., Moura Neto V. T3 affects cerebellar astrocyte proliferation, GFAP and fibronectin organization. Neuroreport 1995, 6:293-296.
36. Faria J., Romão L., Martins S., Alves T., Mendes F.A., De Faria G.P., Hollanda R., Takiya C., Chimelli L., Morandi V., de Souza J.M., Garcia-Abreu J., Moura Neto V. Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation 2006, 74:562-572.
37. Erlich R.B., Kahn S.A., Lima F.R.S., Muras A.G., Martins R.A.P., Linden R., Chiarini L.B., Martins V.R., Moura-Neto V. STI1 promotes glioma proliferation through MAPK and PI3K pathways. Glia 2007, 55:1690-1698.
38. Morandi V., Cherradi S.E., Lambert S., Fauvel-Lafève F., Legrand Y.J., Legrand C. Proinflammatory cytokines (interleukin-1 beta and tumor necrosis factor-alpha) down regulate synthesis and secretion of thrombospondin by human endothelial cells. J. Cell. Physiol. 1994, 160:367-377.
39. Nunes S., Outeiro-Bernstein M.A., Juliano L., Vardiero F., Nader H.B., Woods A., Legrand C., Morandi V. Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1. J. Cell. Physiol. 2008, 214:828-837.
40. Figueiredo C.C., De Lima O.C., De Carvalho L., Lopes-Bezerra L.M., Morandi V. The in vitro interaction of Sporothrix schenckii with human endothelial cells is modulated by cytokines and involves endothelial surface molecules. Microb. Pathog. 2004, 36:177-188.
41. Cominetti M.R., Terruggi C.H., Ramos O.H., Fox J.W., Mariano-Oliveira A., De Freitas M.S., Figueiredo C.C., Morandi V., Selistre-de-Araujo H.S. Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro. J. Biol. Chem. 2004, 279:18247-18255.
42. Huang W., Chiquet-Ehrismann R., Moyano J.V., Garcia-Pardo A., Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res. 2001, 61:8586-8594.
43. Ruiz C., Huang W., Hegi M.E., Lange K., Hamou M.F., Fluri E., Oakeley E.J., Chiquet-Ehrismann R.R., Orend G. Growth promoting signaling by tenascin-C. Cancer Res. 2004, 64:7377-7785.
44. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244:143-163.
45. Zagzag D., Shiff B., Jallo G.I., Greco M.A., Blanco C., Cohen H., Hukin J., Allen J.C., Friedlander D.R. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res. 2002, 62:2660-2668.
46. Chung C.Y., Murphy-Ullrich J.E., Erickson H.P. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol. Biol. Cell 1996, 7:883-892.
47. Saito Y., Shiota Y., Nihisaka M., Owaki T., Shimamura M., Fukai F. Inhibition of angiogenesis by a tenascin-C peptide which is capable of activating beta1-integrins. Biol. Pharm. Bull. 2008, 31:1003-1007.
48. Orend G., Chiquet-Ehrismann R. Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp. Cell Res. 2000, 261:104-110.
49. Orend G., Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244:143-163.
50. Orend G., Hunter T., Ruoslahti E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Oncogene 1998, 16:2575-2583.
51. Behrem S., Zarkovic K., Eskinja N., Jonic N. Distribution pattern of tenascin-C in glioblastoma - correlation with angiogenesis and tumor cell proliferation. Pathol. Oncol. Res. 2005, 11:229-235.
52. Bian X.W., Jiang X.F., Chen J.H., Bai J.S., Dai C., Wang Q.L., Lu J.Y., Zhao W., Xin R., Liu M.Y., Shi J.Q., Wang J.M. Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas. Int. Immunopharmacol. 2006, 6:90-99.
53. Falchetti M.L., Mongiardi M.P., Fiorenzo P., Petrucci G., Pierconti F., D'Agnano I., D'Alessandris G., Alessandri G., Gelati M., Ricci-Vitiani L., Maira G., Larocca L.M., Levi A., Pallini R. Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int. J. Cancer 2008, 122:1236-1242.
54. Chiquet-Ehrismann R., Kalla P., Pearson C.A., Beck K., Chiquet M. Tenascin interferes with fibronectin action. Cell 1988, 53:383-390.
55. Woods A., Couchman J.R. Syndecan 4 heparan sulfate proteoglycan is a selectively enriched and widespread focal adhesion component. Mol. Biol. Cell 1994, 5:183-192.
56. Orend G., Huang W., Olayioye M.A., Hynes N.E., Chiquet-Ehrismann R. Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 2003, 22:3917-3926.
57. Swindle C.S., Tran K.T., Johnson T.D., Banerjee P., Mayes A.M., Griffith L., Wells A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J. Cell Biol. 2001, 154:459-468.
58. Yokosaki Y., Monis H., Chen J., Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J. Biol. Chem. 1996, 271:24144-24150.
59. Chung C.Y., Zardi L., Erickson H.P. Binding of tenascin-C to soluble fibronectin and matrix fibrils. J. Biol. Chem. 1995, 270:29012-29017.
60. Ingham K.C., Brew S.A., Erickson H.P. Localization of a cryptic binding site for tenascin on fibronectin. J. Biol. Chem. 2004, 279:28132-28135.
61. To W.S., Midwood K.S. Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol. 2010, 29:573-585.
62. Lu P., Sternlicht M.D., Werb Z. Comparative mechanisms of branching morphogenesis in diverse systems. J. Mammary Gland Biol. Neoplasia 2006, 11:213.
63. Kass L., Erler J.T., Dembo M., Weaver V.M. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int. J. Biochem. Cell Biol. 2007, 39:1987-1994.
64. Arroyo A.G., Iruela-Arispe M.L. Extracellular matrix, inflammation, and the angiogenic response. Circulation Res. 2010, 86:226-235.
65. Astrof A., Hynes R. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175.
66. Sakai T., Larsen M., Yamada K.M. Fibronectin requirement in branching morphogenesis. Nature 2003, 423:876-881.
67. To W.S., Midwood K.S. Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin. J. Biol. Chem. 2011, 286:14881-14891.
68. Whitby D.J., Ferguson M.W. The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 1991, 112:651-668.
69. Kusubata M., Hirota A., Ebihara T., Kuwaba K., Matsubara Y., Sasaki T., Kusakabe M., Tsukada T., Irie S., Koyama Y. Spatiotemporal changes of fibronectin, tenascin-C, fibulin-1, and fibulin-2 in the skin during the development of chronic contact dermatitis. J. Invest. Dermatol. 1999, 113:906-912.